DEF 14A: GlucoTrack Seeks Stockholder Approval for Equity Plan, Reverse Stock Split to Maintain Nasdaq Listing

GlucoTrack is asking stockholders to approve a new equity incentive plan and a reverse stock split to maintain its Nasdaq listing at its upcoming annual meeting.

Summary

• GlucoTrack, Inc. is holding its 2023 Annual Meeting of Stockholders on April 26, 2024.
• The meeting will address several key proposals, including the adoption of a 2024 Equity Incentive Plan, the election of six directors, and a reverse stock split.
• The proposed reverse stock split aims to increase the company's stock price to maintain compliance with Nasdaq's minimum bid price requirement, with a ratio between 1-for-5 and 1-for-30.
• Stockholders will also vote to ratify the appointment of Fahn Kanne & Co. as the company's independent registered public accounting firm for the fiscal year ended December 31, 2023.
• Additionally, a non-binding advisory vote will be held to determine the frequency of future say-on-pay votes regarding executive compensation (every one, two, or three years).
• The Board of Directors unanimously recommends voting FOR Proposals 1, 3, and 4, FOR the approval of each of the Director Nominees in Proposal 2, and for THREE YEARS for Proposal 5.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily focusing on procedural matters related to the annual meeting and required approvals. The discussion of the reverse stock split introduces some uncertainty, but the overall sentiment is moderately positive as the company is taking steps to address its listing compliance.

Positives

• The reverse stock split could improve the marketability and liquidity of GlucoTrack's Common Stock.
• The 2024 Equity Incentive Plan is designed to attract, retain, and motivate employees, directors, and consultants.
• The Board is actively addressing the Nasdaq minimum bid price requirement to avoid delisting.
• The company is engaging with stockholders on executive compensation through advisory votes.

Negatives

• The reverse stock split may decrease the liquidity of GlucoTrack's Common Stock.
• There is no guarantee that the reverse stock split will increase the stock price or maintain Nasdaq compliance.
• Delisting from Nasdaq could adversely affect the liquidity of GlucoTrack's Common Stock.
• The company has incurred significant net losses in recent years ($(7,096,000) in 2023 and $(4,412,000) in 2022).

Risks

• Failure to maintain compliance with Nasdaq listing requirements could result in delisting.
• The reverse stock split may not increase the stock price as intended.
• A decline in the market price of GlucoTrack's Common Stock after the reverse stock split could result in a greater percentage decline than would occur in the absence of a reverse stock split.
• The company's future performance will impact the stock price regardless of the reverse stock split.

Future Outlook

The company aims to regain compliance with Nasdaq's minimum bid price requirement through the reverse stock split and continue to operate on the Nasdaq Capital Market.

Management Comments

• The Board strongly believes that the Reverse Stock Split is necessary to maintain our listing on The Nasdaq Capital Market.
• The Board unanimously recommends that the stockholders vote FOR each of Proposal 1, Proposal 3 and Proposal 4, FOR the approval of each of the Director Nominees in Proposal 2 and a vote for THREE YEARS for Proposal 5.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. Equity incentive plans are standard tools for attracting and retaining talent in competitive industries.

Comparison to Industry Standards

• Reverse stock splits are often used by companies like Gevo, Inc. and BioPharmX Corporation to regain compliance with Nasdaq listing requirements.
• Equity incentive plans are common across the medical device industry, with companies like Medtronic and DexCom utilizing them to align employee and shareholder interests.
• The annual limitation on awards to non-employee directors is comparable to industry standards, with companies like Insulet Corp. having similar limits in place.

Stakeholder Impact

• Stockholders will be impacted by the reverse stock split and the potential dilution from the equity incentive plan.
• Employees, directors, and consultants may benefit from the 2024 Equity Incentive Plan.
• The company's ability to maintain its Nasdaq listing impacts its access to capital and investor confidence.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on April 26, 2024.
• The Board will determine the specific ratio for the reverse stock split if Proposal 3 is approved.
• The company intends to file a registration statement on Form S-8 covering the shares of Common Stock issuable under the 2024 Plan.

Key Dates

Keywords

reverse stock split, equity incentive plan, annual meeting, Nasdaq, proxy statement, stockholders, directors, executive compensation, Fahn Kanne, delisting